Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH
Authors
Keywords
Her2 expression, <em class=EmphasisTypeItalic >HER2</em> (<em class=EmphasisTypeItalic >ERBB2</em>) amplification, Gastric, Esophageal, Gastroesophageal adenocarcinoma, Stomach cancer, SRM-MS, Selected reaction monitoring mass spectrometry, Companion diagnostic, Clinical biomarker assay, Multiplex protein expression analysis in FFPE tissue
Journal
Gastric Cancer
Volume 19, Issue 4, Pages 1066-1079
Publisher
Springer Nature
Online
2015-11-18
DOI
10.1007/s10120-015-0566-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Template for Reporting Results ofHER2 (ERBB2)Biomarker Testing of Specimens From Patients With Adenocarcinoma of the Stomach or Esophagogastric Junction
- (2015) Angela N. Bartley et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Next-Generation Companion Diagnostics: Promises, Challenges, and Solutions
- (2015) Joseph D. Khoury et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study
- (2014) Ann E. McCullough et al. BREAST CANCER RESEARCH AND TREATMENT
- Two Dimensions in Targeting HER2
- (2014) Mark M. Moasser JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment ofHER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
- (2014) Taroh Satoh et al. JOURNAL OF CLINICAL ONCOLOGY
- Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity
- (2014) Daniel V.T. Catenacci Molecular Oncology
- Garbage in, garbage out: A critical evaluation of strategies used for validation of immunohistochemical biomarkers
- (2014) Gillian O'Hurley et al. Molecular Oncology
- Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue
- (2014) Daniel V. T. Catenacci et al. PLoS One
- HER-2/neugene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma
- (2013) Harry H. Yoon et al. CANCER
- Level ofHER2Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab
- (2013) Carlos Gomez-Martin et al. JOURNAL OF CLINICAL ONCOLOGY
- Application of Selected Reaction Monitoring for Multiplex Quantification of Clinically Validated Biomarkers in Formalin-Fixed, Paraffin-Embedded Tumor Tissue
- (2013) Todd Hembrough et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Reply to ‘Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance’
- (2013) Hee Jin Lee et al. MODERN PATHOLOGY
- HER-2 intratumoral heterogeneity
- (2013) Vincenzo Arena et al. MODERN PATHOLOGY
- Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice
- (2013) Natalia Buza et al. MODERN PATHOLOGY
- MET and ERBB2 Are Coexpressed in ERBB2+ Breast Cancer and Contribute to Innate Resistance
- (2013) A. K. Paulson et al. MOLECULAR CANCER RESEARCH
- Clinical significance of intratumoral HER2 heterogeneity in gastric cancer
- (2012) Hee Eun Lee et al. EUROPEAN JOURNAL OF CANCER
- Testing for Discordance at Metastatic Relapse: Does It Matter?
- (2012) Stephen Chia JOURNAL OF CLINICAL ONCOLOGY
- Adverse Prognostic Impact of Intratumor Heterogeneous HER2 Gene Amplification in Patients With Esophageal Adenocarcinoma
- (2012) Harry H. Yoon et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study
- (2012) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance
- (2012) Hyesil Seol et al. MODERN PATHOLOGY
- HER2 testing in gastric cancer: a practical approach
- (2012) Josef Rüschoff et al. MODERN PATHOLOGY
- MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells
- (2012) C.-T. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of four immunohistochemical tests and FISH for measuring Her2 expression in gastric carcinomas
- (2012) Eun Yoon Cho et al. PATHOLOGY
- RON(MST1R)is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma
- (2011) Daniel V.T. Catenacci et al. CANCER BIOLOGY & THERAPY
- A targeted proteomics–based pipeline for verification of biomarkers in plasma
- (2011) Jeffrey R Whiteaker et al. NATURE BIOTECHNOLOGY
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
- (2011) K. Yonesaka et al. Science Translational Medicine
- Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence
- (2011) D. V. T. Catenacci et al. Cancer Discovery
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- The HER2 testing conundrum
- (2010) Malorye Allison NATURE BIOTECHNOLOGY
- Mass spectrometry in high-throughput proteomics: ready for the big time
- (2010) Tommy Nilsson et al. NATURE METHODS
- HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing
- (2010) Josef Rüschoff et al. VIRCHOWS ARCHIV
- Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
- (2009) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma
- (2009) Terri A Addona et al. NATURE BIOTECHNOLOGY
- Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer
- (2009) Xiu Li Zhang et al. WORLD JOURNAL OF SURGERY
- Assessment of a HER2 scoring system for gastric cancer: results from a validation study
- (2008) M Hofmann et al. HISTOPATHOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search